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Tranexamic acid for surgical bleeding
Uncertainty over vascular occlusive events warrants an adequately powered RCT
Katharine Ker lecturer, Ian Roberts professor of epidemiology
Clinical Trials Unit, London School of Hygiene & Tropical Medicine, London, UK
Joint replacement accounts for a large share of the 230 million
major operations carried out each year worldwide. Each year
in England and Wales alone there are about 180 000 hip and
knee replacements.1 Bleeding is an important complication, and
many patients require a blood transfusion. One strategy to reduce
surgical bleeding is to use the antifibrinolytic drug tranexamic
acid.
Tranexamic acid inhibits clot breakdown by reducing the binding
of plasminogen to fibrin. A recent systematic review and
meta-analysis of randomised controlled trials showed that
tranexamic acid reduces surgical bleeding and blood transfusion
by about one third.2 However, the effect of the antifibrinolytic
on the risk of vascular occlusive events remains uncertain.
Perioperative myocardial infarction often goes undetected as
many patients do not experience ischaemic symptoms.3
Nevertheless, an increased cardiac troponin level, a sensitive
marker of myocardial injury, is common after major surgery
and is associated with appreciable morbidity and mortality.4
In a linked article (doi:10.1136/bmj.g4829), the effort by Poeran
and colleagues to resolve the uncertainty about the effect of
tranexamic acid on vascular occlusive events is therefore
welcomed.5 In a retrospective cohort study the authors compared
the outcomes of 20 051 patients who received tranexamic acid
during hip or knee arthroplasty with 852 365 patients who did
not, using data from 510 US hospitals. They found that
tranexamic acid reduces blood transfusion with no increase in
vascular occlusive events, even after adjusting for patient
characteristics and comorbidities.
Can we now conclude that tranexamic acid is safe for routine
use in joint replacement surgery? Giving a drug that reduces
blood clot breakdown to patients at increased risk of vascular
occlusive events must surely be based on reliable evidence.
Although any increase or decrease in risk is likely to be
moderate, because of the hundreds of thousands of older adults
who undergo joint replacement surgery each year even a
moderate effect could be important.
Reliable assessment of moderate effects requires strict control
of random error and bias.6 Does the study by Poeran and
colleagues fulfil these criteria?
Control of random error means big studies with large numbers
of outcome events, and with over 872 000 patients Poeran and
colleagues’ study is certainly big. However, rigorous control of
bias means proper randomisation and here the study falls short.
As the authors acknowledge, unmeasured or residual
confounding is a large threat to validity that can be dealt with
only by randomisation. The authors’ defence that trials have
limited “generalizability to more general populations” confuses
statistical and scientific inference.Whereas statistical inference,
the process of using sample information to make inferences
about the population from which it was drawn, is helped by
having a representative sample, scientific inference involves
making valid conclusions about biology.7
Valuable insights into the effects of drugs can be obtained even
from patients who are unrepresentative of those in whom the
drug will be used. The finding of the Clinical Randomisation
of an Antifibrinolytic in Significant Haemorrhage (CRASH-2)
trial that tranexamic acid reduces death from bleeding in adults
with trauma was generalised to children, with an adult dose
recommended in children over 12 years and a weight related
dose for younger children, even though this age group was
explicitly excluded from the trial.8 But is there any good
biological reason why tranexamic acid would work in a 20 year
old and not a in 12 year old? Generalisability is not “established”
by data from “actual everyday practice” but depends on valid
information about treatment effects and informed judgment
about the factors that may be relevant to the drug’s mechanism
of action.7
Treatments that reduce bleeding often increase the risk of
thrombosis. According to the summary of product
characteristics,9 tranexamic acid is contraindicated in patients
with a history of arterial or venous thrombosis. However, in the
CRASH-2 trial there were fewer vascular occlusive deaths
associated with tranexamic acid and a statistically significant
reduction in fatal and non-fatal myocardial infarction.10 The
pathogenesis of perioperative myocardial infarction includes
an imbalance in myocardial oxygen supply and demand, rupture
of coronary artery plaque, and platelet activation. By reducing
surgical bleeding, tranexamic acid might reduce the
perioperative tachycardia that increases myocardial oxygen
demand and prevent the decrease in haemoglobin level
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responsible for reduced myocardial oxygen supply.11
Furthermore, plasmin is a potent mediator of inflammation and
by inhibiting plasmin production, tranexamic acid might reduce
the inflammatory response thought to contribute to rupture of
coronary artery plaque.11
If tranexamic acid reduces rather than increases the risk of
myocardial infarction in patients requiring surgery, it could be
a highly cost effective way to improve surgical safety.11 The
large reduction in the risk of myocardial infarction reported by
Poeran and colleagues is consistent with this hypothesis.
Although it would be premature to recommend the routine use
of tranexamic acid in general and orthopaedic surgery, it is
surely time to resolve this uncertainty in an adequately powered
randomised controlled trial.
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